Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Int Immunopharmacol ; 10(11): 1344-53, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20831918

ABSTRACT

The blood vessels are one of the important target tissues for the mediators of inflammation and allergy; further cytokines affect them in a number of ways. We review the use of the isolated blood vessel mounted in organ baths as an important source of pharmacological information. While its use in the bioassay of vasoactive substances tends to be replaced with modern analytical techniques, contractility assays are effective to evaluate novel synthetic drugs, generating robust potency and selectivity data about agonists, partial agonists and competitive or insurmountable antagonists. For instance, the human umbilical vein has been used extensively to characterize ligands of the bradykinin B(2) receptors. Isolated vascular segments are live tissues that are intensely reactive, notably with the regulated expression of gene products relevant for inflammation (e.g., the kinin B(1) receptor and inducible nitric oxide synthase). Further, isolated vessels can be adapted as assays of unconventional proteins (cytokines such as interleukin-1, proteases of physiopathological importance, complement-derived anaphylatoxins and recombinant hemoglobin) and to the gene knockout technology. The well known cross-talks between different cell types, e.g., endothelium-muscle and nerve terminal-muscle, can be extended (smooth muscle cell interaction with resident or infiltrating leukocytes and tumor cells). Drug metabolism and distribution problems can be modeled in a useful manner using the organ bath technology, which, for all these reasons, opens a window on an intermediate level of complexity relative to cellular and molecular pharmacology on one hand, and in vivo studies on the other.


Subject(s)
Biological Assay , Blood Vessels/drug effects , Inflammation Mediators/pharmacology , Muscle Contraction/drug effects , Muscle, Smooth, Vascular/drug effects , Organ Culture Techniques , Animals , Cell Communication/drug effects , Cell Communication/immunology , Cytokines/immunology , Gene Expression/drug effects , Gene Expression/immunology , Humans , Male , Mice , Muscle Contraction/immunology , Muscle, Smooth, Vascular/immunology , Nitric Oxide Synthase Type II/genetics , Nitric Oxide Synthase Type II/immunology , Peptide Hydrolases/analysis , Peptide Hydrolases/immunology , Rats , Receptor, Bradykinin B2/analysis , Receptor, Bradykinin B2/immunology , Umbilical Veins/drug effects , Umbilical Veins/immunology
2.
Can J Physiol Pharmacol ; 84(11): 1107-19, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17218975

ABSTRACT

Bradykinin (BK)-related peptides are suspected to negatively influence diverse functions in vascular smooth muscle cells (SMCs), notably via stimulation of the inducible B1 receptor (B1R), and have been shown to inhibit the migration of rat SMCs. The present study had several objectives: (i) to test whether B1R mediates the inhibition of migration of arterial SMCs from additional species (the human and the rabbit); (ii) whether B1R density influences this action and whether autocrine NO or prostanoid release modulate it; and (iii) the possible signaling interaction between the B1R and phosphatidylinositol-3 kinase (PI-3K) has been addressed. The peptidase resistant B1R agonist Sar-[D-Phe8]des-Arg9-BK (10 nmol/L - 1 micromol/L) was an inhibitor of migration in human or rabbit arterial SMCs in a wound closure assay, more effectively if the medium composition allowed a high B1R expression (20% fetal bovine serum (FBS) + interleukin-1beta (IL-1beta) in human SMCs, 10% FBS in rabbit cells). The effect of the B1R agonist on motility was abrogated by a B1R antagonist, B-9858, but not by the B2R antagonist Hoe 140; a peptidase-resistant B2R agonist, [Phe8Psi(CH2-NH)-Arg9]BK, had a marginal or no effect on migration. Sar-[D-Phe8]des-Arg9-BK (1 micromol/L) did not significantly influence SMC proliferation. The B1R-mediated inhibition of SMC migration was not affected by pharmacological inhibition of the nitric oxide synthases or cyclooxygenases-1 or -2, but was correlated to an inhibition of PI-3K in both types of SMCs. The inhibition of SMC migration mediated by the kinin B1R is likely independent from NO or prostanoid release, applicable to several species, and correlated to receptor density and the inhibition of PI-3K.


Subject(s)
Cell Movement , Muscle, Smooth, Vascular/metabolism , Myocytes, Smooth Muscle/metabolism , Receptor, Bradykinin B1/metabolism , Signal Transduction , Animals , Aorta/cytology , Aorta/metabolism , Bradykinin/analogs & derivatives , Bradykinin/pharmacology , Cell Movement/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Humans , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/drug effects , Myocytes, Smooth Muscle/drug effects , Nitric Oxide/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Prostaglandins/metabolism , Rabbits , Receptor, Bradykinin B1/drug effects , Signal Transduction/drug effects , Time Factors , Umbilical Veins/cytology , Umbilical Veins/metabolism , Wound Healing/drug effects
3.
Int Immunopharmacol ; 2(13-14): 1729-39, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12489786

ABSTRACT

Two types of receptors (B1R, B2R) for kinins are defined in mammalian species. Comparative experiments involving recombinant fusion proteins consisting of rabbit B1R or B2R fused to GFP-related proteins are exploited to study the regulation of the response to kinins at the receptor level. The following points will be briefly reviewed and supported by some novel data. (1) The constitutive B2Rs are internalized upon agonist stimulation, but completely recycled to the cell surface; however, B2R destruction can be achieved following limited proteolysis (extracellular trypsin, neutrophil proteases), a plausible down-regulation mechanism in pathology. (2) The inducible B1Rs, stimulated by des-Arg9-kinins, are not phosphorylated nor internalized upon agonist stimulation, but rather undergo a reversible redistribution to caveolae-related rafts. B2Rs are also subjected to this translocation, but only transiently (before endocytosis). (3) Based on the analysis of rabbit aortic smooth muscle cells, B1R induction by cytokines is dependent on nuclear factor KB in rabbit vascular tissue, but exogenous kinins acting on either receptor type do not induce B1R expression.


Subject(s)
Receptors, Bradykinin/physiology , Animals , Caveolae/metabolism , Caveolae/physiology , Cell Line , Down-Regulation , Endocytosis/physiology , Endothelium, Vascular/cytology , Endothelium, Vascular/metabolism , Green Fluorescent Proteins , Luminescent Proteins/metabolism , Phosphorylation , Rabbits , Receptor, Bradykinin B1 , Receptor, Bradykinin B2 , Receptors, Bradykinin/agonists , Recombinant Fusion Proteins/metabolism
4.
Am J Physiol Heart Circ Physiol ; 283(1): H227-37, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12063295

ABSTRACT

Kinin B(1) receptor (B(1)R) expression and the importance of the transcription factor nuclear factor (NF)-kappa B in this process were evaluated in models based on the rabbit aorta: freshly isolated tissue (postisolation induction) and cultured smooth muscle cells (SMCs). A 3-h incubation of freshly isolated tissues determined a sharp B(1)R mRNA increase (RT-PCR). Coincubation of tissues with a stimulus (interleukin-1 beta, fetal bovine serum, epidermal growth factor, or cycloheximide) further increased mRNA levels. Cultured SMCs possessed a basal population of surface B(1)Rs ([(3)H]Lys-des-Arg(9)-bradykinin binding) that was upregulated by treatments with the same set of stimuli (binding, mRNA, nuclear runon). Pharmacological inhibitors of NF-kappa B (MG-132, BAY 11-7082, dexamethasone) or actinomycin D reduced the postisolation induction of B(1)Rs in fresh aortic tissue (contractility or mRNA) and the cytokine effect on cells (mRNA, binding). NF-kappa B may be a common mediator of various stimuli that increase B(1)R gene transcription in the rabbit aorta, including tissue isolation, but cycloheximide also stabilizes B(1)R mRNA. The SMC models faithfully mimic the in vivo situation with regard to B(1)R regulation.


Subject(s)
Aorta/metabolism , Muscle, Smooth, Vascular/metabolism , NF-kappa B/metabolism , Nitriles , Organic Chemicals , Receptors, Bradykinin/biosynthesis , Sulfones , Animals , Antineoplastic Agents/pharmacology , Aorta/cytology , Aorta/drug effects , Blood Proteins/pharmacology , Cells, Cultured , Dexamethasone/pharmacology , Dose-Response Relationship, Drug , Epidermal Growth Factor/pharmacology , Interleukin-1/pharmacology , Leupeptins/pharmacology , Male , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/drug effects , Nucleic Acid Synthesis Inhibitors/pharmacology , Protein Synthesis Inhibitors/pharmacology , RNA, Messenger/metabolism , Rabbits , Receptor, Bradykinin B1 , Receptors, Bradykinin/genetics , Reverse Transcriptase Polymerase Chain Reaction , Up-Regulation/drug effects , Up-Regulation/physiology , Vasoconstrictor Agents/pharmacology , Vasodilator Agents/pharmacology
5.
Mol Pharmacol ; 61(3): 546-53, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11854434

ABSTRACT

The kallikrein-kinin system, activated during inflammatory conditions and the regulation of specific cardiovascular and renal functions, includes two G protein-coupled receptors for bradykinin (BK)-related peptides. The B(1) receptor (B(1)R) subtype is not believed to undergo agonist-induced phosphorylation and endocytosis. A conjugate made of the rabbit B(1)R fused with the yellow variant of green fluorescent protein (YFP) was expressed in mammalian cells. In COS-1 or human embryonic kidney (HEK) 293 cells, the construction exhibited a nanomolar affinity for the agonist radioligand [(3)H]Lys-des-Arg(9)-BK or the antagonist ligand [(3)H]Lys-[Leu(8)]des-Arg(9)-BK and a pharmacological profile virtually identical to that of wild-type B(1)R. Lys-des-Arg(9)-BK stimulation of HEK 293 cells stably expressing B(1)R-YFP but not stimulation of untransfected cells released [(3)H]arachidonate in a phospholipase A(2) assay. B(1)R-YFP was visualized as a continuous labeling of the plasma membranes in stably transfected HEK 293 cells (confocal microscopy). Addition of Lys-des-Arg(9)-BK (1-100 nM) rapidly concentrated the receptor-associated fluorescence into multiple aggregates that remained associated with the plasma membrane (no significant internalization) and colocalized with caveolin-1. This reaction was slowly reversible upon agonist washing at 37 degrees C and prevented pretreatment with a B(1)R antagonist. beta-Cyclodextrin treatment, which extracts cholesterol from membranes and disrupts caveolae-related rafts, prevented agonist-induced redistribution of B(1)R-YFP but not the PLA(2) activation mediated by this receptor. The agonist radioligand copurified with caveolin-1 to a greater extent than the tritiated antagonist in buoyant fractions of HEK 293 cells treated with the ligands. Agonist-induced cellular translocation of the kinin B(1)R to caveolae-related rafts without endocytosis is a novel variation on the theme of G protein-coupled receptor adaptation.


Subject(s)
Caveolae/metabolism , Kallidin/analogs & derivatives , Kallidin/pharmacology , Membrane Microdomains/metabolism , Receptors, Bradykinin/metabolism , beta-Cyclodextrins , Animals , Antigens, Human Platelet/analysis , Bacterial Proteins/metabolism , Biological Transport/drug effects , Bradykinin/metabolism , COS Cells , Caveolae/drug effects , Caveolin 1 , Caveolins/metabolism , Cell Fractionation , Cells, Cultured , Cyclodextrins/pharmacology , Endocytosis/physiology , Green Fluorescent Proteins , Humans , Luminescent Proteins/metabolism , Membrane Microdomains/drug effects , Rabbits , Receptor, Bradykinin B1 , Receptors, Bradykinin/agonists , Subcellular Fractions , Transfection , Tritium
SELECTION OF CITATIONS
SEARCH DETAIL
...